Abstract: An apparatus comprises a first controller configured to control at least the flow rate of a polymerization inhibitor or acrylonitrile product to a first location where the two are mixed. The apparatus comprises a first on-line analyzer configured to measure polymerization inhibitor concentration in the acrylonitrile product at a second location, the second location downstream of the first location. The first on-line analyzer is configured to provide information relating to the measured inhibitor concentration at the second location to the first controller, the first controller configured to process the information from the first on-line analyzer and to adjust at least a first operating parameter of a first addition device if the measured inhibitor concentration at the second location is outside a first predetermined condition. A second controller and a second on-line analyzer are provided to provide similar control of water addition to acrylonitrile product.
Type:
Grant
Filed:
May 13, 2015
Date of Patent:
June 6, 2017
Assignee:
Ineos Europe AG
Inventors:
Timothy Robert McDonel, Jay Robert Couch, David Rudolph Wagner, Paul Trigg Wachtendorf
Abstract: Provided are compounds of formula (I), wherein X, Y, Z, W, V, R2, R3 and m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.
Type:
Grant
Filed:
June 18, 2012
Date of Patent:
May 30, 2017
Assignee:
AGIOS PHARMACEUTICALS, INC
Inventors:
Sheldon Cao, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Xuefei Tan, Jeremy Travins, Shunqi Yan, Zhixiong Ye
Abstract: The present invention relates to a process for the preparation of carboxamide derivatives of formula (I) R N O N N CF2H C H3F starting from 1-methyl-3-difluormethyl-.5-fluoro-1H-pyrazole-4-carbonyl halides in absence of an acid acceptor.
Type:
Grant
Filed:
November 8, 2013
Date of Patent:
May 23, 2017
Inventors:
Werner Lindner, Sergii Pazenok, Frank Volz
Abstract: The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g. cystic fibrosis), scarring, neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease and Parkinson's disease), autoimmune diseases (e.g. multiple sclerosis and coeliac disease), thrombosis, proliferative disorders (e.g. cancers), AIDS, psoriasis and inflammation (e.g. chronic inflammatory diseases).
Type:
Grant
Filed:
October 9, 2013
Date of Patent:
May 23, 2017
Assignee:
ASTON UNIVERSITY
Inventors:
Martin Griffin, Daniel Rathbone, Leonas Eduard Badarau
Abstract: A production method of the present invention is a method for producing a halohydantoin compound in which method a composition including a halohydantoin compound and an impurity is treated, the method including the step of adding the composition to a mixed solvent of water and an organic solvent and washing the composition.
Abstract: The present invention discloses a class of water soluble taxane derivatives, a method for treating tumor using the same, use thereof as anti-tumor drugs and use thereof in the preparation of anti-tumor drugs. The water soluble taxane derivatives have the general formula (I-1), (I-2) or (I-3): wherein, R1 is H or methyl; R2 is H, methyl or acetyl; R3 is phenyl or OC(CH3)3; X is H, C1-6 alkyl or F; Y is F or C1-6 alkyl substituted with one or more F; n is 1, 2, 3, 4, 5 or 6; W is NR4R5.A or R4 and R5 are each independently H, C1-6 alkyl optionally substituted with phenyl, or C3-6 cycloalkyl; m is 0, 1, 2 or 3; and A is a pharmaceutically acceptable acid.
Type:
Grant
Filed:
February 16, 2015
Date of Patent:
May 16, 2017
Assignee:
JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD
Inventors:
Qingeng Li, Tao Wang, Gang Chen, Yuanzhong Wang, Wei Mao, Lingguo Zeng, Tong Wu, Dahai Chen
Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Type:
Grant
Filed:
May 24, 2013
Date of Patent:
May 16, 2017
Assignees:
The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
Inventors:
Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
Abstract: The present invention discloses a class of water-soluble propofol derivatives, preparation method thereof, anesthetization method using the same, use thereof as prodrugs and use thereof in the preparation of intravenous anesthetics. The water-soluble propofol derivatives have the general formula (I); wherein X is H or F, Y is F or alkyl substituted by one or more F, n is 1, 2, 3, 4, 5 or 6, W is W1 or W2; W1 is NR1R2.A or R1 and R2 are each independently H, alkyl optionally substituted with phenyl, or cycloalkyl, m is 0, 1, 2 or 3, A is a pharmaceutically acceptable acid, W2 is COOM1/t or OPO3(M)2/t or PO3(M)2/t; M is a metal ion, an ammonium ion or a basic amino acid cation which can form a salt with an acid radical; t is the charge number of M.
Type:
Grant
Filed:
February 16, 2015
Date of Patent:
May 9, 2017
Assignee:
JIANGSU NHWALUOKANG PHARMCEUTICAL RESEARCH AND DEVELOPMENT CO., LTD
Inventors:
Qingeng Li, Tao Wang, Tong Wu, Lingguo Zeng, Yuanzhong Wang, Wei Mao, Gang Chen
Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
Abstract: The present invention relates to a process for the cyclopropanation with ethylene carbonate or ethylene sulfate of a compound of formula (II): wherein G is —CN or —COOR in which R is a C1-C4 straight or branched alkyl X and Y are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, R1O— and R1S— wherein R1 is C1-C4 straight or branched alkyl chain.
Type:
Grant
Filed:
June 20, 2014
Date of Patent:
March 28, 2017
Assignee:
ZACH SYSTEMS S.P.A.
Inventors:
Massimo Verzini, Livius Cotarca, Alberto Guidi, Alfonso Melloni, Paolo Maragni
Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
March 21, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Yan Shi, Hao Zhang, Peter T. W. Cheng, Shiwei Tao
Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.
Type:
Grant
Filed:
April 8, 2013
Date of Patent:
March 21, 2017
Assignees:
UNIVERSITY OF SOUTH FLORIDA, THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Chad Dickey, Umesh Jinwal, Laurent Calcul, Bill J. Baker, Matthew Lebar
Abstract: The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
Type:
Grant
Filed:
October 17, 2014
Date of Patent:
March 7, 2017
Assignees:
AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
Inventors:
Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
Abstract: The present invention relates to alpha hydroxy amides including compounds of formula I: and related compounds and their use in the prophylaxis and treatment of inflammatory disorders and diseases, wherein T1, T2, W and RW have the meanings given in claim 1.
Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
Type:
Grant
Filed:
October 17, 2014
Date of Patent:
March 7, 2017
Assignees:
AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
Inventors:
Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
Abstract: Disclosed are methods for screening for the binding affinity of chemical entities to other bioactive molecules. The screened chemical entities may be utilized in pharmaceutical composition or therapeutic methods for treating disease or disorders associated with the bioactive molecules including NEDD4-1.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
March 7, 2017
Assignee:
Northwestern University
Inventors:
Alexander V. Statsyuk, Stefan G. Kathman
Abstract: Compounds of formula (I) wherein R1, R4, R8, X and Y as defined herein are provided as useful for the inhibition of certain types of cancer cells, amongst others, breast cancer cells, or for the manufacture of anti-cancer agents.
Abstract: Provided are a polycyclic pyrazolinone derivative indicated by general formula (1) (in the formula, R1, X1, X2, X3, and Y indicate the definitions provided in the Specification) and a herbicide comprising same as effective component thereof.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 28, 2017
Assignees:
Sagami Chemical Research Institute, Kaken Pharmaceutical Co., Ltd.
Abstract: Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.
Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
February 28, 2017
Assignee:
Allergan, Inc.
Inventors:
Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst